Bone metastatic breast cancer cells display downregulation of PKC-ζ with enhanced glutamine metabolism.

BACKGROUND:Breast cancer is the most commonly diagnosed cancer among women and its metastases results in poor survival rates in patients. The ability to alter metabolism is a key attribute cancer cells use to survive within different metastatic microenvironments and cause organ failure. We hypothesized that evaluation of metabolic alterations within tumor cells could provide a better understanding of cancer metastasis. Therefore, to investigate underlying metabolic alterations during metastases, we utilized human MDA-MB-231 and mouse 4T1 models that closely mimic human breast cancer metastasis. METHODS:The glycolysis and glutamine pathway-related changes were examined in bone metastatic cells by XF-24 extracellular flux analyzer and western blotting. The expression levels of genes related to metabolism were examined by PCR arrays. RESULTS:The MDA-MB-231 cells isolated after bone metastases showed reduced glucose uptake and glycolysis compared to parental cells, suggesting that these cells could alter metabolic requirements for survival. To understand these metabolic changes, we investigated glutamine, a common and naturally occurring non-essential amino acid. Interestingly, in reduced glucose conditions both cell lines showed dependence on glutamine for cell survival, and with glutamine withdrawal significantly increasing apoptotic cell death. Glutamine was also critical for normal cell proliferation even in the presence of high glucose concentrations. To further understand this metabolic switch in metastatic cells, we examined the genes related to metabolism and identified a more than seven-fold downregulation of protein kinase C zeta expression levels in bone-derived MDA-MB-231 cells compared to the parental population. The levels were also significantly reduced in metastatic 4T1 cells compared to non-metastatic MT1A2 cells. Since duanyu1531-ζ deficiency promotes glutamine utilization via the serine biosynthesis pathway, we examined glutamine metabolism. The ectopic expression of duanyu1531-ζ inhibited glutamine conversion to glutamate, while mutant duanyu1531-ζ reversed this effect. Furthermore, the gene expression levels of enzymes involved in serine biosynthesis, phosphoserine phosphatase (PSPH), phosphoserine aminotransferase (PSAT1), and phosphoglycerate dehydrogenase (PHGDH) showed upregulation following glucose deprivation with duanyu1531-ζ deficiency. The PHGDH upregulation was inhibited by ectopically expressing wild type but not mutated duanyu1531-ζ in glucose-deprived conditions. CONCLUSIONS:Our results support the upregulation of serine biosynthesis pathway genes and downregulation of duanyu1531-ζ as potential metabolic alterations for bone metastatic breast cancer cells.

KEYWORDS: {{ getKeywords(articleDetailText.words) }}